Biotech News

Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

AnaptysBio, Inc. (ANAB)AnaptysBio, Inc.Earnings

Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth Jemperli approved in the U.S. as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair

Related news

AnaptysBio, Inc.

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck...

Recent company news

Stock data

Close
47.40 USD
Market cap
1.49B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States